NCDC cautions against Dexamethsaone as COVID-19 infection treatment


The Nigeria Centre for Disease Control (NCDC) warns on Tuesday that Dexamethsaone has not been approved for use in the treatment of COVID-19 patients.

Dexamethsaone ,widely used low-dose steroid ,which have been hailed as a major breakthrough by scientists in the United Kingdom ,has been found to considerably reduce the risk of dying from COVID-19.

However, the NCDC is yet to approve the drug for COVID-19 patients treatment ,as well as the WHO, it said.

In a statement in Abuja, the NCDC said: “The Nigeria Centre for Disease Control (NCDC) is aware of recent outcomes from a UK-Government funded clinical trial for COVID-19.

“The results support the use of Dexamethsaone as a possible treatment to reduce the risk of death among COVID-19 patients, who require oxygen or mechanical ventilation.

“Please note that the Government of Nigeria has not validated or approved any treatment for COVID-19. In addition, the use of Dexamethasone for COVID-19 treatment has not been validated by WHO.

“We are aware of ongoing clinical trials conducted by scientists in the UK and will work with our sister agencies to evaluate this emerging data on the use of Dexamethasone. We will inform the general public on outcomes following scientific review and validation.”

Reported by: Fatimah Oyesanmi

Total Page Visits: 545 - Today Page Visits: 1

Comment here